Mark D. Tyson, II, M.D., M.P.H.

  1. Urologist



  1. Phoenix, Arizona



Mark D. Tyson II, M.D., is a urologic oncologist, with subspecialty interest in bladder cancer. His clinical focus includes:

  • Treatments for muscle invasive and nonmuscle invasive bladder cancer.
  • Robotic and open cystectomy
  • Ileal conduits and orthotopic neobladders
  • Intravesical therapy for nonmuscle invasive bladder cancer
  • Understanding and improving quality of life for patients with bladder cancer
  • Blue light cystoscopy, including in-office flexible blue light.

In addition to his clinical activities, Dr. Tyson is active in research and education, providing mentorship to trainees. He authors expert content and publishes regularly in scientific journals. He is currently recruiting patients for multiple clinical trials for patients with bladder cancer:

  • SWOG S1602: A phase III randomized trial to evaluate the influence of BCG strain differences and T-cell priming with intradermal BCG before intravesical therapy for BCG-naive high-grade non-muscle invasive bladder cancer.
  • TAR-200-103: A multicenter study evaluating safety and efficacy of TAR-200 in subjects with muscle-invasive urothelial carcinoma of the bladder who are ineligible for or refuse cisplatin-based chemotherapy and who are unfit for radical cystectomy.
  • UGN-101: A phase III multicenter trial evaluating the efficacy and safety of MitoGel on ablation of upper urinary tract urothelial carcinoma.
  • UGN-102: A phase IIb, single-arm, multicenter trial to evaluate the efficacy and safety of UGN-102 as a chemoablation agent in patients with low grade non-muscle invasive bladder cancer at intermediate risk of recurrence.
  • KEYNOTE-676: A phase III, randomized comparator-controlled clinical trial to study the efficacy and safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer that is persistent or recurrent following BCG induction.
  • ALLIANCE A031803: A phase II trial of intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.

Dr. Tyson also provides second opinions remotely for newly diagnosed bladder, testis, kidney and prostate cancers. To schedule a video visit, please call 480-342-3868.

  1. Bladder removal
  2. Neobladder reconstruction
  3. Nephrectomy
  4. Orchiectomy
  5. Partial nephrectomy
  6. Retroperitoneal lymph node dissection for testicular cancer
  7. Robotic prostatectomy
  8. Urinary conduit surgery
  • Urothelial carcinoma — bladder cancer and upper tract cancer
  • Renal cell carcinoma
  • Prostate cancer
  • Testis cancer
    MPH - Epidemiology and BiostatisticsHarvard T. H. Chan School of Public Health
    Fellow - Urologic OncologyDepartment of Urologic Surgery, Vanderbilt University School of Medicine
    ResidentUrology Residency, Urology, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
    ResidentSurgery - Preliminary Residency, Surgery, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
    MD - HonorsDartmouth Medical School
    BS - Molecular and Cellular Biology, HonorsUniversity of Arizona


  1. 2019
    UrologyAmerican Board of Urology

Awards and honors

  1. 2019
    Educator of the Year Award (Research)Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Department of Education Administration
  2. 2018
    Kern Scholar, Science of Health Care Delivery Mayo Clinic
  3. 2018
    Christian Haub Family Career Development Award in Cancer ResearchMayo Clinic
  4. 2017
    Best Paper, Resident CornerEuropean Urology
  5. 2017
    Best ReviewerThe Journal of Urology
  6. 2013
    1st Prize, Health Policy Resident Essay ContestWSAUA
  7. 2009
    Alpha Omega AlphaAlpha Omega Alpha Honor Medical Society
  8. 2006
    Magna Cum LaudeUniversity of Arizona

Professional memberships

  1. 2020 - present
    MemberInstitutional Review Board - Wednesday - Mayo Clinic, Institutional Review Board, Mayo Clinic Committees
  2. 2018 - present
    MemberPatient Safety Incident Review Group - AZ, Patient Safety Subcommittee, Continuous Improvement Committee
  3. 2018 - present
    ChairSurgical Quality Subcommittee, Surgical and Procedural Committee, Clinical Practice Committee - Arizona
  4. 2018 - present
    MemberInfection Prevention and Control Subcommittee, Clinical Practice Committee - Arizona, Executive Operations Team - Arizona
  5. 2018 - present
    ChampionSurgical Champion for Mayo Clinic in Arizona, National Surgical Quality Improvement Program, American College of Surgeons
  6. 2017 - present
    MemberBladder Cancer Think Tank, Bladder Cancer Advocacy Network
  7. 2017 - present
    MemberGenitourinary Disease Oriented Group (GU DOG), Department of Urology
  8. 2017 - present
    MemberLower Genitourinary Disease Oriented Group (DOG), Mayo Clinic Task Forces/Work Groups
  9. 2017 - present
    MemberSurgical Quality Subcommittee, Surgical and Procedural Committee, Clinical Practice Committee - Arizona
  10. 2017 - present
    MemberClinical Competency Committee, Urology Residency - Arizona, Mayo Clinic School of Graduate Medical Education
  11. 2015 - present
    MemberSociety of Urologic Oncology
  12. 2015 - present
    MemberVanderbilt Urological Society
  13. 2010 - present
    MemberAmerican Urological Association
  14. 2010 - present
    MemberWestern Section American Urological Association
  15. 2010 - present
    MemberArizona Urological Society
  16. 2010 - present
    MemberPhoenix Urologic Society